Oncopeptides AB (ONCO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncopeptides AB (ONCO) has a cash flow conversion efficiency ratio of 3.676x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-216.49 Million ≈ $-23.30 Million USD) by net assets (Skr-58.89 Million ≈ $-6.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oncopeptides AB (ONCO) defensive interval to measure how many days the company can operate on defensive assets alone.
Oncopeptides AB - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Oncopeptides AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oncopeptides AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncopeptides AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BQE Water Inc
V:BQE
|
-0.045x |
|
RENERGEN LTD CDI/1:1
F:996
|
N/A |
|
Doosan Fuel Cell Co. Ltd. Pfd. Series 1
KO:33626K
|
-0.085x |
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
N/A |
|
Nusa Raya Cipta Tbk
JK:NRCA
|
0.074x |
|
Abra Information Technologies Ltd
TA:BBYL
|
0.015x |
|
Aureus Greenway Holdings Inc. Common Stock
NASDAQ:AGH
|
-0.016x |
|
Argosy Minerals Ltd
AU:AGY
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Oncopeptides AB (2014–2025)
The table below shows the annual cash flow conversion efficiency of Oncopeptides AB from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Oncopeptides AB (ONCO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-58.89 Million ≈ $-6.34 Million |
Skr-222.88 Million ≈ $-23.99 Million |
3.785x | +178.85% |
| 2024-12-31 | Skr54.28 Million ≈ $5.84 Million |
Skr-260.57 Million ≈ $-28.04 Million |
-4.800x | +2.49% |
| 2023-12-31 | Skr56.78 Million ≈ $6.11 Million |
Skr-279.49 Million ≈ $-30.08 Million |
-4.922x | -244.49% |
| 2022-12-31 | Skr294.29 Million ≈ $31.67 Million |
Skr-420.51 Million ≈ $-45.25 Million |
-1.429x | +80.13% |
| 2021-12-31 | Skr210.87 Million ≈ $22.69 Million |
Skr-1.52 Billion ≈ $-163.19 Million |
-7.191x | -219.98% |
| 2020-12-31 | Skr576.90 Million ≈ $62.08 Million |
Skr-1.30 Billion ≈ $-139.53 Million |
-2.247x | -159.38% |
| 2019-12-31 | Skr797.01 Million ≈ $85.77 Million |
Skr-690.57 Million ≈ $-74.32 Million |
-0.866x | +18.00% |
| 2018-12-31 | Skr315.83 Million ≈ $33.99 Million |
Skr-333.73 Million ≈ $-35.91 Million |
-1.057x | -62.69% |
| 2017-12-31 | Skr418.00 Million ≈ $44.98 Million |
Skr-271.50 Million ≈ $-29.22 Million |
-0.650x | +83.59% |
| 2016-12-31 | Skr26.34 Million ≈ $2.83 Million |
Skr-104.26 Million ≈ $-11.22 Million |
-3.959x | -119.49% |
| 2015-12-31 | Skr-2.60 Million ≈ $-279.80K |
Skr-52.81 Million ≈ $-5.68 Million |
20.311x | +591.36% |
| 2014-12-31 | Skr7.61 Million ≈ $818.48K |
Skr-31.44 Million ≈ $-3.38 Million |
-4.134x | -- |
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more